AKTIENANLEIHE - EVOTEC Stock

Certificat

DE000VU9ZFX7

Delayed Deutsche Boerse AG 13:51:32 2024-05-21 EDT
44.68 EUR -1.06% Intraday chart for AKTIENANLEIHE - EVOTEC
Current month-2.38%
1 month-25.60%
Date Price Change
24-05-21 44.68 -1.06%
24-05-20 45.16 -1.14%
24-05-17 45.68 -3.81%
24-05-16 47.49 -2.42%
24-05-15 48.67 +1.93%

Delayed Quote Deutsche Boerse AG

Last update May 21, 2024 at 01:51 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Vontobel Vontobel
WKN VU9ZFX
ISINDE000VU9ZFX7
Date issued 2023-07-18
Strike 25
Maturity 2024-09-20 (122 Days)
Parity 0.03 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 105.3
Lowest since issue 44.42
Spread 21
Spread %4.50%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.685 EUR
Average target price
20.79 EUR
Spread / Average Target
+114.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW